Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Stopped early · Phase 2

Conditions studied: Advanced or Metastatic Solid Tumors, FGFR Mutations, FGFR Translocations

In brief

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumors harboring activating FGFR mutations or translocations.

Key facts

Study ID

NCT04003623

Run by

Incyte Corporation

People needed

1

Starts

2019-10-31

Expected to finish

2020-06-12

Last updated by the study team

2022-05-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic (Stage IIIB or IV) or is surgically unresectable.
• Radiographically measurable disease (per RECIST v1.1 or RANO for primary brain tumors).
• Documentation of an FGFR1-3 gene mutation or translocation.
• Objective disease progression after at least 1 prior therapy.
• Not eligible or able to participate in any other Incyte-sponsored clinical trial.

You may not qualify if…

• Advanced/metastatic bladder cancer or advanced/metastatic cholangiocarcinoma.
• Prior receipt of a selective FGFR inhibitor.
• Current evidence of clinically significant corneal or retinal disorder.
• History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues.

Where it is running

• Compassionate Cancer Care Medical Group — Fountain Valley, California, United States
• Ocala Oncology Center — Ocala, Florida, United States
• Hawaii Cancer Care — Honolulu, Hawaii, United States
• Illinois Cancer Care — Peoria, Illinois, United States
• FMH James M Stockman Cancer Institute — Frederick, Maryland, United States
• New Jersey Cancer Care and Blood Disorders — Belleville, New Jersey, United States
• TriHealth — Cincinnati, Ohio, United States
• Sanford Cancer Center — Sioux Falls, South Dakota, United States
• Mary Crowley Cancer Center — Dallas, Texas, United States
• Oncology Consultants — Houston, Texas, United States
• Utah Cancer Specialists — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.